Baxalta Inc (NYSE:BXLT), better known for its biopharmaceutical offerings, has decided to start the Phase 1 trial of its long-awaited Hemophilia A treatment BAX 826. With this initiation, Baxalta Inc has given BAX 826 to any human for the first time. This recombinant Factor VIII treatment uses PSA (proprietary polysialic acid) technology to ensure that the end results can live up to everyone’s expectations.
Insights of Matter
The BAX 826 treatment is based on world’s most prescribed and trusted FVIII treatment – Antihemophilic Factor (Recombinant). The entire senior management team of Baxalta Inc. is delighted to announce this update and hopes that patients will get rid of their problems with the help of this treatment. According to John Orloff, M.D, Chief Scientific Officer & Head – R&D, Baxalta, the half-life treatment field is evolving at a high pace in today’s time, and Baxalta doesn’t want to miss out any opportunity to make it large.
He further added that Baxalta’s prime objective is to improve the bleed protection for patients suffering from Hemophilia A in different parts of the world. It has been trying for a long time to come up with a perfect direct factor replacement solution to help as many patients as possible. Baxalta looks forward to enrolling around 30 patients in the ongoing research study evaluating the safety of BAX 826. The enrollment procedure is likely to complete by the end of the current year.
BAX 826 is based on the full-length ADVATE and modified with the help of PSA technology, initially licensed from Xenetic Biosciences, Inc. Both the firms have partnered to develop polysialylated blood coagulation factors. Going forward, Baxalta Inc will look to make certain changes in BAX 826 to ensure it can be useful for a maximum number of patients. Details of these improvements will be announced in the near future.
